Theravance Biopharma (TBPH)
(Delayed Data from NSDQ)
$9.35 USD
+0.01 (0.11%)
Updated Apr 22, 2024 11:55 AM ET
After-Market: $9.45 +0.10 (1.07%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TBPH 9.35 +0.01(0.11%)
Will TBPH be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for TBPH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TBPH
Strength Seen in Theravance Bio (TBPH): Can Its 7.6% Jump Turn into More Strength?
Nektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue?
TBPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Is Theravance Bio (TBPH) Down 9% Since Last Earnings Report?
Theravance's (TBPH) Q4 Earnings & Revenues Surpass Estimates
Theravance Biopharma (TBPH) Tops Q4 Earnings and Revenue Estimates
Other News for TBPH
BTIG Research Predicts Over 118% Rally for These 3 Stocks
Theravance Biopharma Breaks Above 200-Day Moving Average - Bullish for TBPH
Veru, Theravance Biopharma, Adial Pharmaceuticals among healthcare movers
Theravance Biopharma initiated with bullish view at BTIG, here's why
Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024